Dacomitinib - Pfizer

Drug Profile

Dacomitinib - Pfizer

Alternative Names: Dacomitinib; PF-00299804; PF-299; PF-299804; PF-804

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Fondazione IRCCS Istituto Nazionale dei Tumori; Pfizer; Seoul National University Hospital; SFJ Pharmaceuticals; University Health Network; University of California, San Diego
  • Class Antineoplastics; Quinazolinones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • Phase II Brain metastases; Gastric cancer; Squamous cell cancer
  • Phase I/II Orofacial cancer
  • No development reported Head and neck cancer; Solid tumours
  • Discontinued Glioblastoma

Most Recent Events

  • 04 Jun 2018 Additional efficacy data from the phase III ARCHER 1050 trial in Non-small cell lung cancer released by Pfizer
  • 28 May 2018 Preregistration for Non-small cell lung cancer (First-line therapy, Monotherapy) in Japan (PO)
  • 04 Apr 2018 Preregistration for Non-small cell lung cancer (First-line therapy, Monotherapy, Metastatic disease) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top